
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is well positioned to capture market share with its innovative drug technology platform, strong regulatory support and potential for a non-dilutive financing opportunity. The company's pipeline shows promising results, with expected milestones in regulatory meetings, initiation of a global Phase 3 trial and potential accelerated approvals in the second half of 2026. However, there are some risks to consider, such as regulatory and financial risks, as well as competition in the market.
Bears say
OS Therapies is heavily focused on developing OST-HER2, their lead drug, for pulmonary metastatic osteosarcoma, a rare and aggressive cancer. With Phase 3 trials expected to launch in 2026 and potential accelerated approval pathways, the company may see market entry in the second half of the year. Despite their promising drug development, the company's current financials indicate a significant risk for investors with a heavy reliance on future success of OST-HER2.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares